Skip to main content
49 search results for:

Multitargeted kinase inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-09-2022 | ESMO 2022 | Conference coverage | Article

    Advanced RCC PFS boost with addition of cabozantinib to first-line dual immunotherapy

    He added that combining the multitargeted tyrosine kinase inhibitor cabozantinib – which is also a standard of care for advanced RCC – with nivolumab plus ipilimumab “has the potential to improve therapeutic outcomes in patients with metastatic RCC of intermediate and poor risk.”

  2. play
    13-09-2022 | ESMO 2022 | Conference coverage | Video

    COSMIC-313 points to first-line triplet option for advanced RCC

    Toni Choueiri tells us about the COSMIC-313 trial evaluating the addition of cabozantinib to nivolumab plus ipilimumab in intermediate- or poor-risk patients with treatment-naïve, advanced renal cell carcinoma.

  3. 23-05-2022 | Multitargeted kinase inhibitors | News | Article

    Oral retinoid may relieve multikinase inhibitor-related hand–foot skin reaction

    A small chart review points to the potential of acitretin for the treatment of refractory hand–foot skin reaction induced by multikinase inhibitors in people with cancer.

  4. 26-04-2022 | Renal cell carcinoma | News | Article

    Cabozantinib shows promise for untreated collecting duct RCC

    The BONSAI trial has demonstrated encouraging efficacy and manageable toxicity of cabozantinib in treatment-naïve patients with metastatic collecting duct renal cell carcinoma.

  5. 21-10-2021 | Renal cell carcinoma | News | Article

    Cabozantinib shows activity against RCC brain metastases

    Cabozantinib has “considerable” intracranial activity in patients with advanced renal cell carcinoma and brain metastases, say the authors of a chart review published in JAMA Oncology .

  6. 19-10-2021 | EMA | News | Article
    approvalsWatch

    EMA gives green light for first-line use of lenvatinib plus pembrolizumab in advanced RCC

    Click through for the details of this positive opinion

  7. 23-04-2021 | Renal cell carcinoma | News | Article

    Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

    The combination of the multitargeted tyrosine kinase inhibitor lenvatinib and the mTOR inhibitor everolimus demonstrated “encouraging anticancer activity” in this patient population and “[t]he safety profile was consistent with the established profile of the study-drug combination,” say the investigators.

  8. play
    19-02-2021 | ASCO GU 2021 | Conference coverage | Video

    TIVO-3 results point to tivozanib activity after RCC progression on axitinib

    Brian Rini describes an analysis of the TIVO-3 advanced renal cell carcinoma trial suggesting that tivozanib offers better outcomes than sorafenib even in patients who have previously received axitinib.

  9. 21-09-2020 | ESMO 2020 | Conference coverage | Article

    Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

    Andrea Apolo explains why she believes the CheckMate 9ER trial has added another option to the armamentarium for treatment-naïve, advanced RCC (4:00) Apolo video After a median follow-up of 18.1 months, PFS as assessed by blinded independent central review was a median of 16.6 months for the 323 participants who were randomly assigned to receive the PD-1 inhibitor nivolumab 240 mg every 2 weeks alongside the multitargeted tyrosine kinase inhibitor (TKI) cabozantinib at a daily dose of 40 mg.

  10. 02-10-2020 | ESMO 2020 | Conference coverage | Article

    Cabozantinib–atezolizumab has ‘encouraging activity’ in advanced RCC

    Previously untreated patients with advanced clear cell renal cell carcinoma benefit from treatment with cabozantinib plus atezolizumab, suggest COSMIC-21 data.

  11. play
    30-09-2020 | ESMO 2020 | Conference coverage | Video

    CheckMate 9ER: Nivolumab–cabozantinib boosts advanced RCC outcomes

    Andrea Apolo gives a top-line overview of the CheckMate 9ER study of nivolumab and cabozantinib, which she believes has added another option to the armamentarium for treatment-naïve, advanced renal cell carcinoma.

  12. 24-07-2020 | Urothelial cancer | News | Article

    Platinum-refractory metastatic urothelial carcinoma responds to cabozantinib

    Cabozantinib has shown promising clinical activity and tolerability in patients with metastatic urothelial carcinoma who have progressed on platinum chemotherapy in a single-center phase 2 trial.

  13. 29-06-2020 | EMA | News | Article
    approvalsWatch

    Entrectinib receives positive decision from EMA

    The announcement includes a second indication, namely for adults with advanced NSCLC harboring ROS1 mutations who have not previously received other ROS1 inhibitors.

  14. 30-01-2020 | Renal cell carcinoma | News | Article

    Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

    Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

  15. 19-02-2020 | ASCO GU 2020 | News | Article

    COSMIC-021: Cabozantinib–atezolizumab duo promising for mCRPC

    Neeraj Agarwal (Huntsman Cancer Institute, Salt Lake City, Utah, USA) and co-authors explained that treatment with either the multitargeted tyrosine kinase inhibitor cabozantinib or the PD-L1 inhibitor atezolizumab as single agents has achieved low objective response rates (ORRs) of 5% and 0%, respectively, in this patient population.

  16. 17-05-2019 | FDA | News | Article
    approvalsWatch

    USA approves first-line avelumab–axitinib for advanced RCC

    The FDA decision to approve the regimen follows the JAVELIN Renal 101 trial’s demonstration of significantly better progression-free survival and objective response rates compared with the multi-target receptor tyrosine kinase inhibitor sunitinib.

  17. 05-03-2019 | Renal cell carcinoma | News | Article

    Cabozantinib efficacy extends to non-clear-cell RCC

    Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.

  18. 05-04-2019 | Non-small-cell lung cancer | News | Article

    Entrectinib has antitumor efficacy in NTRK fusion-positive tumors

    . © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors Atezolizumab, larotrectinib approvals announced by FDA

  19. 19-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Pembrolizumab–axitinib boosts untreated advanced RCC survival

    Progression-free survival – a co-primary endpoint – was also significantly improved with the combination of the PD-1 inhibitor and the VEGFR tyrosine kinase inhibitor, at a median of 15.1 months compared with 11.1 months for sunitinib, and a significant 31% reduced risk for progression or death with the combination.

  20. 20-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Tivozanib improves refractory advanced RCC outcomes

    The trial compared tivozanib – a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3 – with sorafenib, enrolling 350 patients who had received two or three prior systemic regimens for advanced RCC, including at least one VEGFR tyrosine kinase inhibitor.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.